Medicamen Biotech Limited (NSE:MEDICAMEQ)
239.00
-6.65 (-2.71%)
Jun 8, 2026, 12:48 PM IST
Medicamen Biotech Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 312.64 | 37.59 | 147.86 | 207.79 | 38.25 |
Cash & Short-Term Investments | 312.64 | 37.59 | 147.86 | 207.79 | 38.25 |
Cash Growth | 731.63% | -74.57% | -28.84% | 443.26% | -1.69% |
Accounts Receivable | 818.28 | 689 | 552.59 | 652.58 | 632.24 |
Other Receivables | - | 246.2 | 223.43 | 219.83 | 196.18 |
Receivables | 844.91 | 935.2 | 776.03 | 872.41 | 828.42 |
Inventory | 700.8 | 621.37 | 593.75 | 450.57 | 270.1 |
Prepaid Expenses | - | 1.72 | 1.57 | 0.65 | 7.35 |
Other Current Assets | 378.99 | 49.62 | 76.73 | 102.21 | 86.26 |
Total Current Assets | 2,237 | 1,645 | 1,596 | 1,634 | 1,230 |
Property, Plant & Equipment | 840.92 | 863.62 | 909.52 | 917.59 | 921.18 |
Other Intangible Assets | 5.72 | 7.42 | 8.98 | 8.98 | 3.6 |
Long-Term Deferred Tax Assets | 31.68 | 28.3 | 25.15 | 18.8 | 4.96 |
Long-Term Deferred Charges | - | 414.22 | 393.73 | 195.12 | 88.17 |
Other Long-Term Assets | 554.65 | 12.45 | 12.19 | 11.07 | 8.65 |
Total Assets | 3,720 | 2,972 | 2,946 | 2,785 | 2,257 |
Accounts Payable | 400.06 | 348.17 | 334.57 | 416.52 | 393.12 |
Accrued Expenses | - | 97.48 | 68.45 | 53.3 | 37.81 |
Short-Term Debt | 416.31 | 295.19 | 295.62 | 233.13 | 192.75 |
Current Portion of Long-Term Debt | - | 5.21 | 2.94 | 15.26 | 14.47 |
Current Income Taxes Payable | 25.86 | 33.24 | 40.63 | 37 | 42.64 |
Current Unearned Revenue | - | - | 3.18 | 21.31 | 14.41 |
Other Current Liabilities | 36.97 | 2.33 | 100.17 | 49.22 | 31.71 |
Total Current Liabilities | 879.2 | 781.62 | 845.55 | 825.74 | 726.91 |
Long-Term Debt | 61.53 | 37.34 | 12.56 | 8.7 | 50.74 |
Pension & Post-Retirement Benefits | - | 17.77 | 14.63 | 13.16 | 10.98 |
Long-Term Deferred Tax Liabilities | - | -0.03 | - | - | - |
Other Long-Term Liabilities | 23.66 | 4.27 | 2.93 | 3.45 | 3.62 |
Total Liabilities | 964.38 | 840.98 | 875.67 | 851.03 | 792.24 |
Common Stock | 135.63 | 127.15 | 127.15 | 126.51 | 122.17 |
Additional Paid-In Capital | - | 1,023 | 1,023 | 978.73 | 677.05 |
Retained Earnings | - | 963.08 | 907.67 | 825.38 | 687.82 |
Comprehensive Income & Other | 2,620 | 5.21 | -7.01 | -12.14 | -22.34 |
Total Common Equity | 2,756 | 2,119 | 2,051 | 1,918 | 1,465 |
Minority Interest | - | 11.98 | 18.92 | 15.66 | - |
Shareholders' Equity | 2,756 | 2,131 | 2,070 | 1,934 | 1,465 |
Total Liabilities & Equity | 3,720 | 2,972 | 2,946 | 2,785 | 2,257 |
Total Debt | 477.84 | 337.74 | 311.12 | 257.09 | 257.96 |
Net Cash (Debt) | -165.19 | -300.15 | -163.26 | -49.3 | -219.71 |
Net Cash Per Share | -12.18 | -23.61 | -12.90 | -3.90 | -17.98 |
Filing Date Shares Outstanding | 11.76 | 12.71 | 12.71 | 12.65 | 12.22 |
Total Common Shares Outstanding | 11.76 | 12.71 | 12.71 | 12.65 | 12.22 |
Working Capital | 1,358 | 863.88 | 750.38 | 807.89 | 503.47 |
Book Value Per Share | 234.32 | 166.62 | 161.30 | 151.65 | 119.89 |
Tangible Book Value | 2,750 | 2,111 | 2,042 | 1,910 | 1,461 |
Tangible Book Value Per Share | 233.84 | 166.04 | 160.60 | 150.94 | 119.60 |
Land | - | 9.42 | 9.42 | 9.42 | 9.42 |
Buildings | - | 374.91 | 373.19 | 371.88 | 370.28 |
Machinery | - | 985.95 | 966.94 | 907.24 | 853.66 |